An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes - N. Mcgowan; J. Rucker; R. Yehuda; M. Agrawal; H. Simmons; S. Das; G. Goodwin (Neuroscience Applied, 2026)